Eric Eichhorn is a Cardiology physician. OpenAlex indexes 128 publications with 7,170 citations (h-index 41); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7777 Forest Ln
Suite C339
Dallas, TX 752302571
Telephone
972-566-8855Registry record last updated 13 Jan 2022.
Clinical trials
- Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure
Sponsor: Celladon Corporation
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
45 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Inspire Medical Systems, Inc.Program year20252 payments
- Actelion Pharmaceuticals US, Inc.Program year202511 payments
- ABIOMEDProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
89.4%Beta blocker27.5%Metoprolol Succinate54%Carvedilol22%Bisoprolol Fumarate9%Atenolol8%Nebivolol Hcl7%Sotalol2%Part D<11 patientsStatin11.6%Atorvastatin Calcium67%Rosuvastatin Calcium23%Simvastatin6%Pravastatin Sodium4%Part D<11 patients+ 18 more classes in this area
Blood & clotting
7.9%Factor Xa inhibitor5.9%Eliquis91%Xarelto9%Part D<11 patientsVitamin K antagonist1.2%Warfarin Sodium100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
2.1%SGLT2 inhibitor1.5%Farxiga62%Jardiance38%Part D<11 patientsPotassium supplement0.6%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Coronary artery disease, coronary revascularization, and outcomes in chronic advanced systolic heart failure
International Journal of Cardiology
2010 - Effects of Peripheral Arterial Disease on Outcomes in Advanced Chronic Systolic Heart Failure
Circulation Heart Failure
2009 - Role of a Percutaneous Ventricular Assist Device in Decision Making for a Cardiac Transplant Program
The Annals of Thoracic Surgery
2009
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”